For the quarter ending 2025-09-30, ALT had -$121,869K decrease in cash & cash equivalents over the period. -$11,897K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -19,014 | -41,721 |
| Stock-based compensation expense | 3,554 | 7,581 |
| Depreciation of property and equipment | 27 | 59 |
| Accretion of discounts on short-term investments | 196 | 1,117 |
| Amortization of debt discount and costs | 113 | 58 |
| Loss on foreign currency exchange | -86 | -30 |
| Deferred income tax benefit | 0 | -681 |
| Accounts receivable | 524 | -223 |
| Prepaid expenses and other assets | 8 | 1,895 |
| Accounts payable | 3,953 | 640 |
| Accrued expenses and other liabilities | 102 | -2,064 |
| Income tax and r&d incentive receivables | -10 | -2,697 |
| Net cash used in operating activities | -11,897 | -36,190 |
| Proceeds from sales and maturities of short-term investments | 0 | 143,589 |
| Purchases of short-term investments | 149,321 | 47,573 |
| Purchases of property and equipment | 0 | 10 |
| Net cash used in investing activities | -149,321 | 96,006 |
| Payments of deferred offering costs | 0 | 298 |
| Proceeds from term loan | 0 | 15,000 |
| Payment for debt issuance costs | 322 | 404 |
| Proceeds from issuance of common stock in at-the-market offerings, net | 39,517 | 72,571 |
| Proceeds from issuance of common stock from employee stock purchase plan | 121 | 170 |
| Proceeds from exercises of stock options | 33 | 8 |
| Payments for tax withholding in share-based compensation | 0 | 684 |
| Net cash provided by (used in) financing activities | 39,349 | 86,363 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | -121,869 | 146,179 |
| Cash and cash equivalents at beginning of period | 36,968 | - |
| Cash and cash equivalents at end of period | 61,278 | - |
Altimmune, Inc. (ALT)
Altimmune, Inc. (ALT)